• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Response to letter: a critical appraisal of the DATA trial analysis on the prognostic and predictive value of the luminal-like subtype.

作者信息

Lammers S W M, Tjan-Heijnen V C G, Geurts S M E, Vriens I J H

机构信息

Maastricht University Medical Centre, Maastricht, Netherlands.

Maastricht University Medical Centre, Maastricht, Netherlands.

出版信息

ESMO Open. 2025 May;10(5):105070. doi: 10.1016/j.esmoop.2025.105070. Epub 2025 Apr 15.

DOI:10.1016/j.esmoop.2025.105070
PMID:40239367
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12020828/
Abstract
摘要

相似文献

1
Response to letter: a critical appraisal of the DATA trial analysis on the prognostic and predictive value of the luminal-like subtype.对信件的回复：对腔面样亚型的预后和预测价值的DATA试验分析的批判性评估。
ESMO Open. 2025 May;10(5):105070. doi: 10.1016/j.esmoop.2025.105070. Epub 2025 Apr 15.
2
Letter re: A critical appraisal of the DATA trial analysis on the prognostic and predictive value of the luminal-like subtype.关于《 luminal样亚型的预后和预测价值的DATA试验分析的批判性评价》的信件
ESMO Open. 2025 May;10(5):105067. doi: 10.1016/j.esmoop.2025.105067. Epub 2025 Apr 15.
3
Response to letter re: The prognostic and predictive value of the luminal-like subtype in hormone receptor-positive breast cancer: an analysis of the DATA trial.对关于“激素受体阳性乳腺癌中腔面样亚型的预后和预测价值：DATA试验分析”的信件的回复
ESMO Open. 2025 May;10(5):105068. doi: 10.1016/j.esmoop.2025.105068. Epub 2025 Apr 16.
4
Letter re: The prognostic and predictive value of the luminal-like subtype in hormone receptor-positive breast cancer: an analysis of the DATA trial.信件回复：管腔样亚型在激素受体阳性乳腺癌中的预后及预测价值：DATA试验分析
ESMO Open. 2025 May;10(5):105066. doi: 10.1016/j.esmoop.2025.105066. Epub 2025 Apr 30.
5
The prognostic and predictive value of the luminal-like subtype in hormone receptor-positive breast cancer: an analysis of the DATA trial.激素受体阳性乳腺癌中腔面样亚型的预后和预测价值：DATA试验分析
ESMO Open. 2025 Feb;10(2):104154. doi: 10.1016/j.esmoop.2025.104154. Epub 2025 Feb 7.
6
Prognostic Value of the Progesterone Receptor by Subtype in Patients with Estrogen Receptor-Positive, HER-2 Negative Breast Cancer.孕激素受体亚型在雌激素受体阳性、HER-2 阴性乳腺癌患者中的预后价值。
Oncologist. 2019 Feb;24(2):165-171. doi: 10.1634/theoncologist.2018-0176. Epub 2018 Aug 31.
7
Relationship between functional imaging and immunohistochemical markers and prediction of breast cancer subtype: a PET/MRI study.功能成像与免疫组化标志物与乳腺癌亚型预测的关系：一项 PET/MRI 研究。
Eur J Nucl Med Mol Imaging. 2018 Sep;45(10):1680-1693. doi: 10.1007/s00259-018-4010-7. Epub 2018 Apr 25.
8
Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial.激素受体阳性/人表皮生长因子受体 2 阴性早期乳腺癌中基因组或中央分级及免疫组织化学亚型或 IHC4 对预后和预测影响的比较：WSG-AGO EC-Doc 试验。
Ann Oncol. 2016 Jun;27(6):1035-1040. doi: 10.1093/annonc/mdw070. Epub 2016 Feb 18.
9
A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer.初治尿路上皮癌分子分类中的预后基因表达特征可预测新辅助化疗的临床结局：一项尿路上皮癌剂量密集型甲氨蝶呤、长春碱、阿霉素和顺铂联合贝伐单抗的2期试验
Eur Urol. 2016 May;69(5):855-62. doi: 10.1016/j.eururo.2015.08.034. Epub 2015 Sep 3.
10
Identification of a Low-Risk Luminal A Breast Cancer Cohort That May Not Benefit From Breast Radiotherapy.识别低危管腔 A 型乳腺癌队列，该队列可能不需要接受乳房放疗。
J Clin Oncol. 2015 Jun 20;33(18):2035-40. doi: 10.1200/JCO.2014.57.7999. Epub 2015 May 11.

本文引用的文献

1
The prognostic and predictive value of the luminal-like subtype in hormone receptor-positive breast cancer: an analysis of the DATA trial.激素受体阳性乳腺癌中腔面样亚型的预后和预测价值：DATA试验分析
ESMO Open. 2025 Feb;10(2):104154. doi: 10.1016/j.esmoop.2025.104154. Epub 2025 Feb 7.
2
Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial.序贯内分泌治疗后延长辅助芳香化酶抑制（DATA）：一项随机、3 期临床试验。
Lancet Oncol. 2017 Nov;18(11):1502-1511. doi: 10.1016/S1470-2045(17)30600-9. Epub 2017 Oct 12.
3
Tissue microarrays for comparing molecular features with proliferation activity in breast cancer.用于比较乳腺癌分子特征与增殖活性的组织微阵列。
Int J Cancer. 2006 May 1;118(9):2190-4. doi: 10.1002/ijc.21581.
4
Microarrays of bladder cancer tissue are highly representative of proliferation index and histological grade.膀胱癌组织微阵列高度代表增殖指数和组织学分级。
J Pathol. 2001 Jul;194(3):349-57. doi: 10.1002/1096-9896(200107)194:3<349::AID-PATH887>3.0.CO;2-D.